Premium
Circulating matrix metalloproteinases levels and their inhibitors in clinical and experimental hypertension
Author(s) -
Fontana Vanessa,
Silva Pâmela Souza,
Belo Vanessa Almeida,
Antonio Raquel Carros,
Ceron Carla Speroni,
Biagi Celso,
Gerlach Raquel Fernanda,
TanusSantos José Eduardo
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.lb458
Subject(s) - matrix metalloproteinase , medicine , pathophysiology , endocrinology , essential hypertension , blood pressure
The aim of this study was to evaluate circulating levels of metalloproteinases (MMPs) and their inhibitors, tissue inhibitor of MMP (TIMP) and alpha‐2‐macroglobulin (A2M), in human and experimental hypertension. MMP‐2, MMP‐8, MMP‐9, TIMP‐1, TIMP‐2 and A2M plasma levels were determined in 38 untreated hypertensive patients and 33 normotensive subjects. We also assessed plasma levels of MMP‐9 and MMP‐2 and A2M in Spontaneously Hypertensive Rats (SHR) and in Wistar Kyoto (WKY) rats. We found no significant differences in MMP‐2, MMP ‐8, TIMP‐1, TIMP‐2 and A2M levels between the groups. However, hypertensives patients had higher levels of MMP‐9 (p≤0.05) than normotensives. In addition, MMP‐9/A2M and MMP‐8/A2M ratio are significantly higher in hypertension group. Similarly to human hypertension, no change in MMP‐2 and A2M plasma levels was observed in SHR compared to WKY. Also, significantly higher MMP‐9 levels and MMP‐9/A2M ratio were found in hypertensive group. Briefly, our findings show abnormal net plasma MMP‐9 activity in untreated hypertensive patients and in experimental hypertension, reinforcing the relevance of MMPs in pathophysiology of hypertension. Financial Support: CNPq, FAPESP and CAPES